NASDAQ:MDWD - Mediwound Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.90 -0.20 (-2.82 %)
(As of 06/22/2018 05:44 AM ET)
Previous Close$7.10
Today's Range$6.90 - $7.10
52-Week Range$3.56 - $8.25
Volume36,700 shs
Average Volume38,262 shs
Market Capitalization$187.98 million
P/E Ratio-11.13
Dividend YieldN/A
Mediwound logoMediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals


Debt-to-Equity RatioN/A
Current Ratio6.07
Quick Ratio5.75


Trailing P/E Ratio-11.13
Forward P/E Ratio-9.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.50 million
Price / Sales74.66
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book19.17


EPS (Most Recent Fiscal Year)($0.62)
Net Income$-22,140,000.00
Net Margins-904.12%
Return on Equity-226.62%
Return on Assets-36.64%


Outstanding Shares27,050,000

Mediwound (NASDAQ:MDWD) Frequently Asked Questions

What is Mediwound's stock symbol?

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

How were Mediwound's earnings last quarter?

Mediwound Ltd (NASDAQ:MDWD) announced its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The biopharmaceutical company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.57 million. Mediwound had a negative net margin of 904.12% and a negative return on equity of 226.62%. View Mediwound's Earnings History.

When is Mediwound's next earnings date?

Mediwound is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Mediwound.

What price target have analysts set for MDWD?

5 equities research analysts have issued 12-month price objectives for Mediwound's stock. Their predictions range from $8.00 to $14.00. On average, they anticipate Mediwound's stock price to reach $10.00 in the next year. View Analyst Ratings for Mediwound.

Who are some of Mediwound's key competitors?

Who are Mediwound's key executives?

Mediwound's management team includes the folowing people:
  • Mr. Gal Cohen, Pres & CEO (Age 45)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 72)
  • Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 46)
  • Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 52)
  • Dr. Ety Klinger, Chief R&D Officer (Age 56)

Has Mediwound been receiving favorable news coverage?

Media coverage about MDWD stock has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mediwound earned a coverage optimism score of 0.18 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Mediwound's major shareholders?

Mediwound's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (7.68%) and Wells Fargo & Company MN (0.45%). View Institutional Ownership Trends for Mediwound.

Which major investors are selling Mediwound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd.. View Insider Buying and Selling for Mediwound.

Which major investors are buying Mediwound stock?

MDWD stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Mediwound.

How do I buy shares of Mediwound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mediwound's stock price today?

One share of MDWD stock can currently be purchased for approximately $6.90.

How big of a company is Mediwound?

Mediwound has a market capitalization of $187.98 million and generates $2.50 million in revenue each year. The biopharmaceutical company earns $-22,140,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Mediwound employs 76 workers across the globe.

How can I contact Mediwound?

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]

MarketBeat Community Rating for Mediwound (MDWD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.